NEFTYS PHARMA
Acquired by
FOR TALENTS / UI INVESTISSEMENT / GENEO
NEFTYS PHARMA acquired by FOR TALENTS / UI INVESTISSEMENT / GENEO
Target
NEFTYS PHARMA
Acquirer
FOR TALENTS / UI INVESTISSEMENT / GENEO
Context
In a structured minority growth equity transaction, specialized family capital investment firm For Talents has acquired a minority stake in Neftys Pharma. This strategic operation is executed alongside incumbent financial sponsors UI Investissement and GENEO Capital Entrepreneur, who are rolling over their investments after an initial four-year holding period. The transaction is fundamentally designed to facilitate the intergenerational transmission of the family-owned enterprise from founder Jacques Mignot to his son, Diego Mignot, who officially assumes the presidency. The equity syndication is further supported by a comprehensive financing package provided by a broad syndicate of tier-one banking partners. This transaction represents a textbook succession-driven recapitalization, allowing the founding family to secure a seamless leadership transition while onboarding specialized institutional capital to fuel the next phase of value creation. For the incoming and reinvesting financial sponsors, this platform investment offers a highly attractive risk-return profile, backing a proven management team operating within the non-cyclical, high-growth animal health vertical. The injection of strategic support and patient capital will empower Neftys Pharma to aggressively pursue its strategic roadmap, which is anchored around five core value-creation levers: intensifying market penetration across Europe (particularly Eastern Europe), executing geographic expansion into new international territories, launching new vertical services, developing proprietary brands, and deepening integration with flagship laboratory partners.
NEFTYS PHARMA, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (13.3x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in 1987 and historically originating from the OCP Group, Neftys Pharma operates as a premier wholesale distributor dedicated to veterinary products for animal health and well-being professionals. Operating as a comprehensive one-stop-shop, the company expertly manages the procurement, warehousing, and distribution of a wide array of both medical veterinary products (such as vaccines and pharmaceuticals) and non-medical goods, including specialized nutrition, dietary supplements, and hygiene products. The firm essentially bridges the gap between veterinary pharmaceutical laboratories and a diversified network of end-users, encompassing veterinary clinics, livestock breeders, specialized retail outlets, and pharmacies. Furthermore, the company extends its value proposition by offering dedicated depository services, sales promotion, and tailored support services directly to laboratories. Neftys Pharma stands as a formidable market leader and a premier consolidation platform within the highly fragmented European veterinary distribution sector, currently ranking as the third-largest player in its domestic French market. Its distinctive value proposition is anchored in its comprehensive supply chain capabilities and its unique positioning as an indispensable intermediary within the animal health ecosystem.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with NEFTYS PHARMA
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 06/2022 | UI INVESTISSEMENT / GENEO | NEFTYS PHARMA | FRANCE | Animal Health | A consortium of prominent financial sponsors, led by UI Investissement and supported by GENEO Capital Entrepreneur alongside historical partner Crédit Agricole Centre France, has successfully executed a growth equity investment in Neftys Pharma. The transaction is structured around a €30 million capital increase, injected directly into the company's balance sheet to fuel its ambitious expansion trajectory. Concurrently, the financial sponsors' equity injection is optimally paired with a newly secured, structured debt financing package exceeding €52 million, provided by the firm's historical banking syndicate. This platform investment is fundamentally rooted in a robust value-creation thesis aimed at accelerating the company's aggressive buy-and-build strategy across the fragmented European animal health market. By infusing significant dry powder into the business, the financial consortium provides Neftys Pharma with the requisite firepower to execute highly accretive external growth opportunities, aiming to double its size over the next five years. |
REFERENCES
Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).
Target: neftys pharma